1 Dugger, S. A., Platt, A. & Goldstein, D. B. Drug development in the era of precision medicine. Nat Rev Drug Discov 17, 183-196, doi:10.1038/nrd.2017.226 (2018).
2 Ashley, E. A. Towards precision medicine. Nat Rev Genet 17, 507-522, doi:10.1038/nrg.2016.86 (2016).
3 Janne, P. A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372, 1689-1699, doi:10.1056/NEJMoa1411817 (2015).
4 Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368, 2385-2394, doi:10.1056/NEJMoa1214886 (2013).
5 Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the 'undruggable' cancer targets. Nat Rev Cancer 17, 502-508, doi:10.1038/nrc.2017.36 (2017).
6 Huang, A., Garraway, L. A., Ashworth, A. & Weber, B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov, doi:10.1038/s41573-019-0046-z (2019).
7 Nagel, R., Semenova, E. A. & Berns, A. Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep 17, 1516-1531, doi:10.15252/embr.201643030 (2016).
8 McLornan, D. P., List, A. & Mufti, G. J. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med 371, 1725-1735, doi:10.1056/NEJMra1407390 (2014).
9 Mirza, M. R. et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 375, 2154-2164, doi:10.1056/NEJMoa1611310 (2016).
10 Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917, doi:10.1038/nature03443 (2005).
11 Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69, doi:10.1038/nature10496 nature10496 [pii] (2011).
12 Dvinge, H., Kim, E., Abdel-Wahab, O. & Bradley, R. K. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer 16, 413-430, doi:10.1038/nrc.2016.51 (2016).
13 Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11, 220-228, doi:10.1038/nrm2858 (2010).
14 Chabot, B. & Shkreta, L. Defective control of pre-messenger RNA splicing in human disease. J Cell Biol 212, 13-27, doi:10.1083/jcb.201510032 jcb.201510032 [pii] (2016).
15 Vuong, C. K., Black, D. L. & Zheng, S. The neurogenetics of alternative splicing. Nat Rev Neurosci 17, 265-281, doi:10.1038/nrn.2016.27 nrn.2016.27 [pii] (2016).
16 Inoue, D., Bradley, R. K. & Abdel-Wahab, O. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes Dev 30, 989-1001, doi:10.1101/gad.278424.116 30/9/989 [pii] (2016).
17 Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374, 2209-2221, doi:10.1056/NEJMoa1516192 (2016).
18 Donaires, F. S. et al. Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: a Brazilian cohort screening study. Rev Bras Hematol Hemoter 38, 320-324, doi:S1516-8484(16)30053-6 [pii] 10.1016/j.bjhh.2016.06.002 (2016).
19 Meggendorfer, M. et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120, 3080-3088, doi:10.1182/blood-2012-01-404863 blood-2012-01-404863 [pii] (2012).
20 Salton, M. & Misteli, T. Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy. Trends Mol Med 22, 28-37, doi:10.1016/j.molmed.2015.11.005 S1471-4914(15)00213-0 [pii] (2016).
21 Lee, S. C. & Abdel-Wahab, O. Therapeutic targeting of splicing in cancer. Nat Med 22, 976-986, doi:10.1038/nm.4165 nm.4165 [pii] (2016).
22 Bonnal, S., Vigevani, L. & Valcarcel, J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11, 847-859, doi:10.1038/nrd3823 nrd3823 [pii] (2012).
23 Corkery, D. P., Holly, A. C., Lahsaee, S. & Dellaire, G. Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response. Nucleus 6, 279-288, doi:10.1080/19491034.2015.1062194 (2015).
24 Colwill, K. et al. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 15, 265-275 (1996).
25 Ghosh, G. & Adams, J. A. Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J 278, 587-597, doi:10.1111/j.1742-4658.2010.07992.x (2011).
26 Singh, R. K. & Cooper, T. A. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 18, 472-482, doi:10.1016/j.molmed.2012.06.006 (2012).
27 Dominguez, D. et al. An extensive program of periodic alternative splicing linked to cell cycle progression. Elife 5, doi:10.7554/eLife.10288 e10288 [pii] (2016).
28 Fedorov, O. et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol 18, 67-76, doi:10.1016/j.chembiol.2010.11.009 S1074-5521(10)00444-8 [pii] (2011).
29 Sako, Y. et al. Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. Sci Rep 7, 46126, doi:10.1038/srep46126 srep46126 [pii] (2017).
30 Muraki, M. et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 279, 24246-24254, doi:10.1074/jbc.M314298200 M314298200 [pii] (2004).
31 Hsu, T. Y. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384-388, doi:10.1038/nature14985 nature14985 [pii] (2015).
32 Koh, C. M. et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523, 96-100, doi:10.1038/nature14351 nature14351 [pii] (2015).
33 Dang, C. V. MYC on the path to cancer. Cell 149, 22-35, doi:10.1016/j.cell.2012.03.003 S0092-8674(12)00296-6 [pii] (2012).
34 Kress, T. R., Sabo, A. & Amati, B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer 15, 593-607, doi:10.1038/nrc3984 nrc3984 [pii] (2015).
35 Cermelli, S., Jang, I. S., Bernard, B. & Grandori, C. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 4, doi:10.1101/cshperspect.a014209 a014209 [pii] 4/3/a014209 [pii] (2014).
36 Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target cMyc. Cell 146, 904-917, doi:10.1016/j.cell.2011.08.017 S0092-8674(11)00943-3 [pii] (2011).
37 Horiuchi, D. et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med 22, 1321-1329, doi:10.1038/nm.4213 nm.4213 [pii] (2016).
38 Camarda, R. et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med 22, 427-432, doi:10.1038/nm.4055 nm.4055 [pii] (2016).
39 Kessler, J. D. et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335, 348-353, doi:10.1126/science.1212728 science.1212728 [pii] (2012).
40 Araki, S. et al. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS One 10, e0116929, doi:10.1371/journal.pone.0116929 PONE-D-14-35737 [pii] (2015).
41 Rodgers, J. T., Haas, W., Gygi, S. P. & Puigserver, P. Cdc2-like kinase 2 is an insulinregulated suppressor of hepatic gluconeogenesis. Cell Metab 11, 23-34, doi:10.1016/j.cmet.2009.11.006 S1550-4131(09)00370-2 [pii] (2010).
42 Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods 7, 1009-1015, doi:10.1038/nmeth.1528 nmeth.1528 [pii] (2010).
43 Yoshida, T. et al. CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. Cancer Res 75, 1516-1526, doi:10.1158/0008-5472.CAN-14-2443 0008-5472.CAN-14-2443 [pii] (2015).
44 Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607, doi:10.1038/nature11003 nature11003 [pii] (2012).
45 Malynn, B. A. et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14, 1390-1399 (2000).
46 Bidinosti, M. et al. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency. Science 351, 1199-1203, doi:10.1126/science.aad5487 science.aad5487 [pii] (2016).
47 Funnell, T. et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor. Nat Commun 8, 7, doi:10.1038/s41467-016-0008- 7 10.1038/s41467-016-0008-7 [pii] (2017).
48 Das, S., Anczukow, O., Akerman, M. & Krainer, A. R. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 1, 110-117, doi:10.1016/j.celrep.2011.12.001 (2012).
49 Butt, A. J. et al. The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome. Breast Cancer Res 10, R28, doi:10.1186/bcr1985 bcr1985 [pii] (2008).
50 Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352, doi:10.1038/nature10983 nature10983 [pii] (2012).
51 Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 7, 11479, doi:10.1038/ncomms11479 ncomms11479 [pii] (2016).
52 Fernandez-Martinez, P., Zahonero, C. & Sanchez-Gomez, P. DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol Cell Oncol 2, e970048, doi:10.4161/23723548.2014.970048 970048 [pii] (2015).
53 Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241-247, doi:10.1038/leu.2013.336 leu2013336 [pii] (2014).
54 Shirai, C. L. et al. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun 8, 14060, doi:10.1038/ncomms14060 ncomms14060 [pii] (2017).
55 Lee, S. C. et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med 22, 672-678, doi:10.1038/nm.4097 nm.4097 [pii] (2016).
56 Anczukow, O. et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19, 220-228, doi:10.1038/nsmb.2207 nsmb.2207 [pii] (2012).
57 Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235-239, doi:10.1038/nature09727 nature09727 [pii] (2011).
58 Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189-195, doi:10.1038/nature09730 nature09730 [pii] (2011).
59 Xu, F. et al. Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes. Nat Commun 6, 8806, doi:10.1038/ncomms9806 ncomms9806 [pii] (2015).
60 Kurosawa, N., Yoshioka, M., Fujimoto, R., Yamagishi, F. & Isobe, M. Rapid production of antigen-specific monoclonal antibodies from a variety of animals. BMC Biol 10, 80, doi:10.1186/1741-7007-10-80 1741-7007-10-80 [pii] (2012).
61 Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504, doi:10.1101/gr.1239303 13/11/2498 [pii] (2003).
62 Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1, doi:10.1126/scisignal.2004088 scisignal.2004088 [pii] (2013).
63 Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404, doi:10.1158/2159- 8290.CD-12-0095 2/5/401 [pii] (2012).
64 Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017, doi:10.1200/PO.17.00011 (2017).
65 Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. & Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115, doi:0092-8674(88)90184-5 [pii] (1988).
66 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646- 674, doi:10.1016/j.cell.2011.02.013 (2011).
67 McGranahan, N. & Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 168, 613-628, doi:10.1016/j.cell.2017.01.018 (2017).
68 Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345, doi:10.1038/nature12625 (2013).
69 Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071-1078, doi:10.1038/nature08467 (2009).
70 Kotsantis, P. et al. Increased global transcription activity as a mechanism of replication stress in cancer. Nat Commun 7, 13087, doi:10.1038/ncomms13087 (2016).
71 Dobbelstein, M. & Sorensen, C. S. Exploiting replicative stress to treat cancer. Nat Rev Drug Discov 14, 405-423, doi:10.1038/nrd4553 (2015).
72 Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat Cell Biol 16, 2-9, doi:10.1038/ncb2897 (2014).
73 Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913, doi:10.1038/nature03485 (2005).
74 Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355, doi:10.1126/science.1140735 (2008).
75 Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870, doi:10.1038/nature03482 (2005).
76 Koltun, E. S. et al. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorganic & medicinal chemistry letters 22, 3727-3731, doi:10.1016/j.bmcl.2012.04.024 (2012).
77 Montagnoli, A. et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 4, 357-365, doi:10.1038/nchembio.90 nchembio.90 [pii] (2008).
78 Harrington, P. E. et al. The optimization of aminooxadiazoles as orally active inhibitors of Cdc7. Bioorganic & medicinal chemistry letters 23, 6396-6400, doi:10.1016/j.bmcl.2013.09.055 S0960-894X(13)01129-3 [pii] (2013).
79 Reichelt, A. et al. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem 80, 364-382, doi:10.1016/j.ejmech.2014.04.013 S0223-5234(14)00332-8 [pii] (2014).
80 Kurasawa, O. et al. Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3- dihydrothieno[3,2-d]pyrimidin-4(1H)-ones. Bioorg Med Chem 25, 2133-2147, doi:10.1016/j.bmc.2017.02.021 (2017).
81 Kurasawa, O. et al. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3- methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. Bioorg Med Chem 25, 3658-3670, doi:10.1016/j.bmc.2017.04.044 (2017).
82 Irie, T. et al. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors. Eur J Med Chem 130, 406-418, doi:10.1016/j.ejmech.2017.02.030 (2017).
83 Jiang, W., McDonald, D., Hope, T. J. & Hunter, T. Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication. EMBO J 18, 5703-5713, doi:10.1093/emboj/18.20.5703 (1999).
84 Cho, W. H., Lee, Y. J., Kong, S. I., Hurwitz, J. & Lee, J. K. CDC7 kinase phosphorylates serine residues adjacent to acidic amino acids in the minichromosome maintenance 2 protein. Proc Natl Acad Sci U S A 103, 11521-11526, doi:10.1073/pnas.0604990103 (2006).
85 Montagnoli, A., Moll, J. & Colotta, F. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res 16, 4503-4508, doi:10.1158/1078- 0432.CCR-10-0185 (2010).
86 Yamada, M., Masai, H. & Bartek, J. Regulation and roles of Cdc7 kinase under replication stress. Cell Cycle 13, 1859-1866, doi:10.4161/cc.29251 (2014).
87 Kulkarni, A. A. et al. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clin Cancer Res 15, 2417-2425, doi:10.1158/1078- 0432.CCR-08-1276 (2009).
88 Montagnoli, A. et al. Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem 281, 10281-10290, doi:10.1074/jbc.M512921200 (2006).
89 Tsuji, T., Ficarro, S. B. & Jiang, W. Essential role of phosphorylation of MCM2 by Cdc7/Dbf4 in the initiation of DNA replication in mammalian cells. Mol Biol Cell 17, 4459-4472, doi:10.1091/mbc.E06-03-0241 (2006).
90 Yin, T. et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther 13, 1442-1456, doi:10.1158/1535- 7163.MCT-13-0849 (2014).
91 Petermann, E., Woodcock, M. & Helleday, T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A 107, 16090-16095, doi:10.1073/pnas.1005031107 (2010).
92 Moiseeva, T. et al. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1. Nat Commun 8, 1392, doi:10.1038/s41467-017-01401-x (2017).
93 Rainey, M. D., Quachthithu, H., Gaboriau, D. & Santocanale, C. DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors. ACS Chem Biol 12, 1893-1902, doi:10.1021/acschembio.7b00117 (2017).
94 Ohashi, A. et al. A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity. PLoS One 10, e0144675, doi:10.1371/journal.pone.0144675 (2015).
95 Montagnoli, A. et al. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res 64, 7110-7116, doi:10.1158/0008-5472.CAN-04- 1547 (2004).
96 Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 7, 428-430, doi:10.1038/nchembio.573 (2011).
97 O'Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & Goodship, J. A. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 33, 497-501, doi:10.1038/ng1129 (2003).
98 Sluder, G. & Nordberg, J. J. The good, the bad and the ugly: the practical consequences of centrosome amplification. Curr Opin Cell Biol 16, 49-54, doi:10.1016/j.ceb.2003.11.006 (2004).
99 Hemerly, A. S., Prasanth, S. G., Siddiqui, K. & Stillman, B. Orc1 controls centriole and centrosome copy number in human cells. Science 323, 789-793, doi:10.1126/science.1166745 (2009).
100 Ferguson, R. L. & Maller, J. L. Cyclin E-dependent localization of MCM5 regulates centrosome duplication. J Cell Sci 121, 3224-3232, doi:10.1242/jcs.034702 (2008).
101 Ferguson, R. L., Pascreau, G. & Maller, J. L. The cyclin A centrosomal localization sequence recruits MCM5 and Orc1 to regulate centrosome reduplication. J Cell Sci 123, 2743-2749, doi:10.1242/jcs.073098 (2010).
102 Lu, F., Lan, R., Zhang, H., Jiang, Q. & Zhang, C. Geminin is partially localized to the centrosome and plays a role in proper centrosome duplication. Biol Cell 101, 273-285, doi:10.1042/BC20080109 (2009).
103 Hossain, M. & Stillman, B. Meier-Gorlin syndrome mutations disrupt an Orc1 CDK inhibitory domain and cause centrosome reduplication. Genes Dev 26, 1797-1810, doi:10.1101/gad.197178.112 (2012).
104 Xu, X. et al. DNA replication licensing factor Cdc6 and Plk4 kinase antagonistically regulate centrosome duplication via Sas-6. Nat Commun 8, 15164, doi:10.1038/ncomms15164 (2017).
105 McDonald, E. R., 3rd et al. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell 170, 577-592 e510, doi:10.1016/j.cell.2017.07.005 (2017).
106 Ohashi, A. et al. Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat Commun 6, 7668, doi:10.1038/ncomms8668 (2015).
1 Dugger, S. A., Platt, A. & Goldstein, D. B. Drug development in the era of precision medicine. Nat Rev Drug Discov 17, 183-196, doi:10.1038/nrd.2017.226 (2018).
2 Ashley, E. A. Towards precision medicine. Nat Rev Genet 17, 507-522, doi:10.1038/nrg.2016.86 (2016).
3 Janne, P. A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372, 1689-1699, doi:10.1056/NEJMoa1411817 (2015).
4 Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368, 2385-2394, doi:10.1056/NEJMoa1214886 (2013).
5 Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the 'undruggable' cancer targets. Nat Rev Cancer 17, 502-508, doi:10.1038/nrc.2017.36 (2017).
6 Huang, A., Garraway, L. A., Ashworth, A. & Weber, B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov, doi:10.1038/s41573-019-0046-z (2019).
7 Nagel, R., Semenova, E. A. & Berns, A. Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep 17, 1516-1531, doi:10.15252/embr.201643030 (2016).
8 McLornan, D. P., List, A. & Mufti, G. J. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med 371, 1725-1735, doi:10.1056/NEJMra1407390 (2014).
9 Mirza, M. R. et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 375, 2154-2164, doi:10.1056/NEJMoa1611310 (2016).
10 Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917, doi:10.1038/nature03443 (2005).
11 Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69, doi:10.1038/nature10496 nature10496 [pii] (2011).
12 Dvinge, H., Kim, E., Abdel-Wahab, O. & Bradley, R. K. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer 16, 413-430, doi:10.1038/nrc.2016.51 (2016).
13 Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11, 220-228, doi:10.1038/nrm2858 (2010).
14 Chabot, B. & Shkreta, L. Defective control of pre-messenger RNA splicing in human disease. J Cell Biol 212, 13-27, doi:10.1083/jcb.201510032 jcb.201510032 [pii] (2016).
15 Vuong, C. K., Black, D. L. & Zheng, S. The neurogenetics of alternative splicing. Nat Rev Neurosci 17, 265-281, doi:10.1038/nrn.2016.27 nrn.2016.27 [pii] (2016).
16 Inoue, D., Bradley, R. K. & Abdel-Wahab, O. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes Dev 30, 989-1001, doi:10.1101/gad.278424.116 30/9/989 [pii] (2016).
17 Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374, 2209-2221, doi:10.1056/NEJMoa1516192 (2016).
18 Donaires, F. S. et al. Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: a Brazilian cohort screening study. Rev Bras Hematol Hemoter 38, 320-324, doi:S1516-8484(16)30053-6 [pii] 10.1016/j.bjhh.2016.06.002 (2016).
19 Meggendorfer, M. et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120, 3080-3088, doi:10.1182/blood-2012-01-404863 blood-2012-01-404863 [pii] (2012).
20 Salton, M. & Misteli, T. Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy. Trends Mol Med 22, 28-37, doi:10.1016/j.molmed.2015.11.005 S1471-4914(15)00213-0 [pii] (2016).
21 Lee, S. C. & Abdel-Wahab, O. Therapeutic targeting of splicing in cancer. Nat Med 22, 976-986, doi:10.1038/nm.4165 nm.4165 [pii] (2016).
22 Bonnal, S., Vigevani, L. & Valcarcel, J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11, 847-859, doi:10.1038/nrd3823 nrd3823 [pii] (2012).
23 Corkery, D. P., Holly, A. C., Lahsaee, S. & Dellaire, G. Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response. Nucleus 6, 279-288, doi:10.1080/19491034.2015.1062194 (2015).
24 Colwill, K. et al. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 15, 265-275 (1996).
25 Ghosh, G. & Adams, J. A. Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J 278, 587-597, doi:10.1111/j.1742-4658.2010.07992.x (2011).
26 Singh, R. K. & Cooper, T. A. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 18, 472-482, doi:10.1016/j.molmed.2012.06.006 (2012).
27 Dominguez, D. et al. An extensive program of periodic alternative splicing linked to cell cycle progression. Elife 5, doi:10.7554/eLife.10288 e10288 [pii] (2016).
28 Fedorov, O. et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol 18, 67-76, doi:10.1016/j.chembiol.2010.11.009 S1074-5521(10)00444-8 [pii] (2011).
29 Sako, Y. et al. Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. Sci Rep 7, 46126, doi:10.1038/srep46126 srep46126 [pii] (2017).
30 Muraki, M. et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 279, 24246-24254, doi:10.1074/jbc.M314298200 M314298200 [pii] (2004).
31 Hsu, T. Y. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384-388, doi:10.1038/nature14985 nature14985 [pii] (2015).
32 Koh, C. M. et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523, 96-100, doi:10.1038/nature14351 nature14351 [pii] (2015).
33 Dang, C. V. MYC on the path to cancer. Cell 149, 22-35, doi:10.1016/j.cell.2012.03.003 S0092-8674(12)00296-6 [pii] (2012).
34 Kress, T. R., Sabo, A. & Amati, B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer 15, 593-607, doi:10.1038/nrc3984 nrc3984 [pii] (2015).
35 Cermelli, S., Jang, I. S., Bernard, B. & Grandori, C. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 4, doi:10.1101/cshperspect.a014209 a014209 [pii] 4/3/a014209 [pii] (2014).
36 Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target cMyc. Cell 146, 904-917, doi:10.1016/j.cell.2011.08.017 S0092-8674(11)00943-3 [pii] (2011).
37 Horiuchi, D. et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med 22, 1321-1329, doi:10.1038/nm.4213 nm.4213 [pii] (2016).
38 Camarda, R. et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med 22, 427-432, doi:10.1038/nm.4055 nm.4055 [pii] (2016).
39 Kessler, J. D. et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335, 348-353, doi:10.1126/science.1212728 science.1212728 [pii] (2012).
40 Araki, S. et al. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS One 10, e0116929, doi:10.1371/journal.pone.0116929 PONE-D-14-35737 [pii] (2015).
41 Rodgers, J. T., Haas, W., Gygi, S. P. & Puigserver, P. Cdc2-like kinase 2 is an insulinregulated suppressor of hepatic gluconeogenesis. Cell Metab 11, 23-34, doi:10.1016/j.cmet.2009.11.006 S1550-4131(09)00370-2 [pii] (2010).
42 Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods 7, 1009-1015, doi:10.1038/nmeth.1528 nmeth.1528 [pii] (2010).
43 Yoshida, T. et al. CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. Cancer Res 75, 1516-1526, doi:10.1158/0008-5472.CAN-14-2443 0008-5472.CAN-14-2443 [pii] (2015).
44 Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607, doi:10.1038/nature11003 nature11003 [pii] (2012).
45 Malynn, B. A. et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14, 1390-1399 (2000).
46 Bidinosti, M. et al. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency. Science 351, 1199-1203, doi:10.1126/science.aad5487 science.aad5487 [pii] (2016).
47 Funnell, T. et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor. Nat Commun 8, 7, doi:10.1038/s41467-016-0008- 7 10.1038/s41467-016-0008-7 [pii] (2017).
48 Das, S., Anczukow, O., Akerman, M. & Krainer, A. R. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 1, 110-117, doi:10.1016/j.celrep.2011.12.001 (2012).
49 Butt, A. J. et al. The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome. Breast Cancer Res 10, R28, doi:10.1186/bcr1985 bcr1985 [pii] (2008).
50 Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352, doi:10.1038/nature10983 nature10983 [pii] (2012).
51 Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 7, 11479, doi:10.1038/ncomms11479 ncomms11479 [pii] (2016).
52 Fernandez-Martinez, P., Zahonero, C. & Sanchez-Gomez, P. DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol Cell Oncol 2, e970048, doi:10.4161/23723548.2014.970048 970048 [pii] (2015).
53 Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241-247, doi:10.1038/leu.2013.336 leu2013336 [pii] (2014).
54 Shirai, C. L. et al. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun 8, 14060, doi:10.1038/ncomms14060 ncomms14060 [pii] (2017).
55 Lee, S. C. et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med 22, 672-678, doi:10.1038/nm.4097 nm.4097 [pii] (2016).
56 Anczukow, O. et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19, 220-228, doi:10.1038/nsmb.2207 nsmb.2207 [pii] (2012).
57 Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235-239, doi:10.1038/nature09727 nature09727 [pii] (2011).
58 Pasqualucci, L. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189-195, doi:10.1038/nature09730 nature09730 [pii] (2011).
59 Xu, F. et al. Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes. Nat Commun 6, 8806, doi:10.1038/ncomms9806 ncomms9806 [pii] (2015).
60 Kurosawa, N., Yoshioka, M., Fujimoto, R., Yamagishi, F. & Isobe, M. Rapid production of antigen-specific monoclonal antibodies from a variety of animals. BMC Biol 10, 80, doi:10.1186/1741-7007-10-80 1741-7007-10-80 [pii] (2012).
61 Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504, doi:10.1101/gr.1239303 13/11/2498 [pii] (2003).
62 Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1, doi:10.1126/scisignal.2004088 scisignal.2004088 [pii] (2013).
63 Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404, doi:10.1158/2159- 8290.CD-12-0095 2/5/401 [pii] (2012).
64 Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017, doi:10.1200/PO.17.00011 (2017).
65 Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. & Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115, doi:0092-8674(88)90184-5 [pii] (1988).
66 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646- 674, doi:10.1016/j.cell.2011.02.013 (2011).
67 McGranahan, N. & Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 168, 613-628, doi:10.1016/j.cell.2017.01.018 (2017).
68 Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345, doi:10.1038/nature12625 (2013).
69 Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071-1078, doi:10.1038/nature08467 (2009).
70 Kotsantis, P. et al. Increased global transcription activity as a mechanism of replication stress in cancer. Nat Commun 7, 13087, doi:10.1038/ncomms13087 (2016).
71 Dobbelstein, M. & Sorensen, C. S. Exploiting replicative stress to treat cancer. Nat Rev Drug Discov 14, 405-423, doi:10.1038/nrd4553 (2015).
72 Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat Cell Biol 16, 2-9, doi:10.1038/ncb2897 (2014).
73 Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913, doi:10.1038/nature03485 (2005).
74 Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355, doi:10.1126/science.1140735 (2008).
75 Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870, doi:10.1038/nature03482 (2005).
76 Koltun, E. S. et al. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorganic & medicinal chemistry letters 22, 3727-3731, doi:10.1016/j.bmcl.2012.04.024 (2012).
77 Montagnoli, A. et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol 4, 357-365, doi:10.1038/nchembio.90 nchembio.90 [pii] (2008).
78 Harrington, P. E. et al. The optimization of aminooxadiazoles as orally active inhibitors of Cdc7. Bioorganic & medicinal chemistry letters 23, 6396-6400, doi:10.1016/j.bmcl.2013.09.055 S0960-894X(13)01129-3 [pii] (2013).
79 Reichelt, A. et al. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem 80, 364-382, doi:10.1016/j.ejmech.2014.04.013 S0223-5234(14)00332-8 [pii] (2014).
80 Kurasawa, O. et al. Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3- dihydrothieno[3,2-d]pyrimidin-4(1H)-ones. Bioorg Med Chem 25, 2133-2147, doi:10.1016/j.bmc.2017.02.021 (2017).
81 Kurasawa, O. et al. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3- methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. Bioorg Med Chem 25, 3658-3670, doi:10.1016/j.bmc.2017.04.044 (2017).
82 Irie, T. et al. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors. Eur J Med Chem 130, 406-418, doi:10.1016/j.ejmech.2017.02.030 (2017).
83 Jiang, W., McDonald, D., Hope, T. J. & Hunter, T. Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication. EMBO J 18, 5703-5713, doi:10.1093/emboj/18.20.5703 (1999).
84 Cho, W. H., Lee, Y. J., Kong, S. I., Hurwitz, J. & Lee, J. K. CDC7 kinase phosphorylates serine residues adjacent to acidic amino acids in the minichromosome maintenance 2 protein. Proc Natl Acad Sci U S A 103, 11521-11526, doi:10.1073/pnas.0604990103 (2006).
85 Montagnoli, A., Moll, J. & Colotta, F. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res 16, 4503-4508, doi:10.1158/1078- 0432.CCR-10-0185 (2010).
86 Yamada, M., Masai, H. & Bartek, J. Regulation and roles of Cdc7 kinase under replication stress. Cell Cycle 13, 1859-1866, doi:10.4161/cc.29251 (2014).
87 Kulkarni, A. A. et al. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clin Cancer Res 15, 2417-2425, doi:10.1158/1078- 0432.CCR-08-1276 (2009).
88 Montagnoli, A. et al. Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases. J Biol Chem 281, 10281-10290, doi:10.1074/jbc.M512921200 (2006).
89 Tsuji, T., Ficarro, S. B. & Jiang, W. Essential role of phosphorylation of MCM2 by Cdc7/Dbf4 in the initiation of DNA replication in mammalian cells. Mol Biol Cell 17, 4459-4472, doi:10.1091/mbc.E06-03-0241 (2006).
90 Yin, T. et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther 13, 1442-1456, doi:10.1158/1535- 7163.MCT-13-0849 (2014).
91 Petermann, E., Woodcock, M. & Helleday, T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A 107, 16090-16095, doi:10.1073/pnas.1005031107 (2010).
92 Moiseeva, T. et al. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1. Nat Commun 8, 1392, doi:10.1038/s41467-017-01401-x (2017).
93 Rainey, M. D., Quachthithu, H., Gaboriau, D. & Santocanale, C. DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors. ACS Chem Biol 12, 1893-1902, doi:10.1021/acschembio.7b00117 (2017).
94 Ohashi, A. et al. A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity. PLoS One 10, e0144675, doi:10.1371/journal.pone.0144675 (2015).
95 Montagnoli, A. et al. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res 64, 7110-7116, doi:10.1158/0008-5472.CAN-04- 1547 (2004).
96 Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 7, 428-430, doi:10.1038/nchembio.573 (2011).
97 O'Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & Goodship, J. A. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 33, 497-501, doi:10.1038/ng1129 (2003).
98 Sluder, G. & Nordberg, J. J. The good, the bad and the ugly: the practical consequences of centrosome amplification. Curr Opin Cell Biol 16, 49-54, doi:10.1016/j.ceb.2003.11.006 (2004).
99 Hemerly, A. S., Prasanth, S. G., Siddiqui, K. & Stillman, B. Orc1 controls centriole and centrosome copy number in human cells. Science 323, 789-793, doi:10.1126/science.1166745 (2009).
100 Ferguson, R. L. & Maller, J. L. Cyclin E-dependent localization of MCM5 regulates centrosome duplication. J Cell Sci 121, 3224-3232, doi:10.1242/jcs.034702 (2008).
101 Ferguson, R. L., Pascreau, G. & Maller, J. L. The cyclin A centrosomal localization sequence recruits MCM5 and Orc1 to regulate centrosome reduplication. J Cell Sci 123, 2743-2749, doi:10.1242/jcs.073098 (2010).
102 Lu, F., Lan, R., Zhang, H., Jiang, Q. & Zhang, C. Geminin is partially localized to the centrosome and plays a role in proper centrosome duplication. Biol Cell 101, 273-285, doi:10.1042/BC20080109 (2009).
103 Hossain, M. & Stillman, B. Meier-Gorlin syndrome mutations disrupt an Orc1 CDK inhibitory domain and cause centrosome reduplication. Genes Dev 26, 1797-1810, doi:10.1101/gad.197178.112 (2012).
104 Xu, X. et al. DNA replication licensing factor Cdc6 and Plk4 kinase antagonistically regulate centrosome duplication via Sas-6. Nat Commun 8, 15164, doi:10.1038/ncomms15164 (2017).
105 McDonald, E. R., 3rd et al. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell 170, 577-592 e510, doi:10.1016/j.cell.2017.07.005 (2017).
106 Ohashi, A. et al. Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat Commun 6, 7668, doi:10.1038/ncomms8668 (2015).